Ganetespib "ripe for partnership": Roth

Roth Capital is out with some positive commentary on Synta Pharmaceuticals (SNTA +10.5%) following the announcement of new clinical trials for ganetespib

"We continue to look towards interim analysis from the GALAXY-2 trial in NSCLC in H2 and top-line data in H1 2015," analyst Joseph Pantginis says, adding that "as the ganetespib profile continues to broaden, [he] continues to believe that the drug is ripe for a partnership in the relative near term."

Price target is $27, representing upside of 295% from Thursday's close.

From other sites
Comments (1)
  • TruffelPig
    , contributor
    Comments (4208) | Send Message
    The recent clinical data were not so hip I'd say.....
    10 Jan 2014, 08:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs